This Article Full Text Full Text (PDF) CME: Take the course for this article: Adjuvant Hormonal Therapy in Peri- and Postmenopausal Breast Cancer eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ryan, P. D. Articles by Goss, P. E. Search for Related Content PubMed Articles by Ryan, P. D. Articles by Goss, P. E.

Breast Cancer

Adjuvant Hormonal Therapy in Peri- and Postmenopausal Breast Cancer

Massachusetts General Hospital, Boston, Massachusetts, USA

Key Words. Breast cancer • Aromatase inhibitors • Adjuvant • Hormonal • Postmenopause • Perimenopause • Review

Correspondence: Paula D. Ryan, M.D., Ph.D., Massachusetts General Hospital,Cox 640, 100 Blossom Street, Boston, Massachusetts 02114, USA. Telephone: 617-726-5046; Fax: 617-724-3166; e-mail: pdryan{at}partners.org

Tamoxifen has been the mainstay of endocrine treatment for early-stage breast cancer in both premenopausal and postmenopausal women for many years. Since 2001, the results of several large, randomized, clinical trials have provided evidence that aromatase inhibitor (AI) therapy, either upfront or in sequence after tamoxifen, improves disease-free survival and, in certain patients, overall survival for postmenopausal patients with hormone receptor-positive breast cancer. Thus far, with relatively short-term follow-up, AIs have been generally safe and well tolerated among the population of patients treated in these adjuvant trials. However, important side effects such as musculoskeletal and bone-related problems, including the risk for osteoporosis and fractures, remain of concern and warrant continued monitoring and follow-up. Several questions regarding the appropriate AI to use and the timing of AI therapy remain unresolved, and ongoing studies will help address these issues. Caution is warranted in the use of AIs in perimenopausal women, including those that develop chemotherapy-induced amenorrhea, and clinical evidence supports the role for AI use in postmenopausal women only. Areas of active investigation include the mechanisms of resistance to endocrine therapy with tamoxifen and AIs and clinical strategies to overcome this resistance.

This article has been cited by other articles:

				C. G. Jakobsen, N. Rasmussen, A.-V. Laenkholm, and H. J. Ditzel Phage Display Derived Human Monoclonal Antibodies Isolated by Binding to the Surface of Live Primary Breast Cancer Cells Recognize GRP78 Cancer Res., October 1, 2007; 67(19): 9507 - 9517. [Abstract] [Full Text] [PDF]

				M. P. Hardman, J. J. Roman, A. F. Burnett, and A. D. Santin Metastatic Uterine Leiomyosarcoma Regression Using an Aromatase Inhibitor Obstet. Gynecol., August 1, 2007; 110(2): 518 - 520. [Abstract] [Full Text] [PDF]

				B. Moy and P. E. Goss Lapatinib: Current Status and Future Directions in Breast Cancer Oncologist, November 1, 2006; 11(10): 1047 - 1057. [Abstract] [Full Text] [PDF]